This ADC product is comprised of an anti-CFD monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CFD; complement factor D (adipsin); D component of complement (adipsin) , DF, PFD, properdin factor D; complement factor D; ADN; properdin factor D; C3 convertase activator; complement factor D preproprotein; D component of complement (adipsin); DF; PFD;
- Target Entrez Gene ID
- 1675
- Overview
- This gene encodes a member of the S1, or chymotrypsin, family of serine peptidases. This protease catalyzes the cleavage of factor B, the rate-limiting step of the alternative pathway of complement activation. This protein also functions as an adipokine,Ɇ
ADC Antibody
- Overview
- Chimeric Anti-CFD IgG1-kappa-Fab’ fragment , Lampalizumab
- Generic name
- Lampalizumab
ADC Linker
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products